Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol

32Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Anthracycline, a widely used anti-cancer agent, can elicit irreversible cardiomyopathy called anthracycline-induced cardiomyopathy (ACM). In this report, we describe 5 cases of severe chronic heart failure due to ACM effectively treated with the beta-blocker, carvedilol. Their left ventricular function as well as cardiac symptoms were persistently improved after treatment with carvedilol, suggesting that carvedilol may be an effective therapeutic strategy for ACM as demonstrated in other forms of chronic heart failure.

Cite

CITATION STYLE

APA

Mukai, Y., Yoshida, T., Nakaike, R., Mukai, N., Iwato, K., Kyo, T., & Kaseda, S. (2004). Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Internal Medicine, 43(11), 1087–1088. https://doi.org/10.2169/internalmedicine.43.1087

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free